-
MGI Tech Co., Ltd Partners with Human Cell Atlas Consortium to Advance Cell Mapping
•
China-based gene sequencing specialist, MGI Tech Co., Ltd, (SHA: 688114) has announced a commercial collaboration with the Human Cell Atlas (HCA) consortium, marking a significant step forward in the human cell mapping initiative. This partnership aims to expand access to MGI’s proprietary products within the HCA network by offering discounted…
-
U.S. House of Representatives to Review the Biosecure Act Amid Legislative Hurdles
•
The U.S. House of Representatives is slated to take up the contentious Biosecure Act the week commencing September 9, as indicated on a website associated with the legislative body. Initially introduced in January, the bill’s trajectory has been marked by delays, raising questions about its potential progression through the House…
-
Pfizer Partners with Quotient Therapeutics for Somatic Mutations Research in Cardiovascular and Renal Diseases
•
NEW YORK—Pfizer Inc., a pharmaceutical giant listed on the New York Stock Exchange (NYSE: PFE), has entered into a research collaboration with Quotient Therapeutics, a Cambridge, Massachusetts-based biotech firm. The partnership will focus on analyzing somatic mutations in diseased patient tissue, with a goal of uncovering new therapeutic approaches for…
-
China’s Sansure Biotech Launches Approved Kit for Alzheimer’s and Cardiovascular Risk Assessment
•
Sansure Biotech Inc. (SHA: 688289), a China-based leader in molecular diagnostics, has secured marketing approval from the National Medical Products Administration (NMPA) for its human ApoE gene polymorphism nucleic acid detection kit, utilizing the PCR fluorescent probe method. This kit is classified as a Category III medical device. The detection…
-
Agilent Technologies and Shanghai Majorbio Bio-pharm Ink Deal to Transform Life Science Research in China
•
Agilent Technologies (NYSE: A), a global leader in life sciences, diagnostics, and applied chemical markets, has announced a strategic collaboration with Shanghai Majorbio Bio-pharm Technology Co., Ltd, a prominent biopharmaceutical company in China. This partnership will provide Majorbio with access to Agilent’s cutting-edge sample quality control solutions and its flagship…
-
Novogene and Becton, Dickinson Partner to Advance Single Cell Sequencing Technologies
•
Novogene (SHA: 688315), a genomic services and solutions provider based in Beijing and operating globally, has entered into a strategic partnership with US medical technology giant Becton, Dickinson and Co. (BD). The collaboration focuses on the single cell instrument HT Xpress and the establishment of a joint laboratory dedicated to…
-
BGI Genomics and Technopark Biogen Launch Astana Genetic Center to Boost Genetic Testing in Central Asia
•
Astana Genetic Center, a collaboration between China’s leading genomics company BGI Genomics Co., Ltd (SHE: 300676) and Kazakhstan’s Technopark Biogen, has officially commenced operations. The center, located within the Kazakhstan National Biotechnology Center, is well-equipped with state-of-the-art gene sequencing and genetic data analysis machinery, aiming to facilitate early disease diagnosis…
-
MGI Tech Partners with Predica Diagnostics to Advance RNA Sequencing in Cancer Detection
•
MGI Tech Co., Ltd, a leading gene sequencing specialist based in China, has announced a strategic collaboration with Predica Diagnostics, a Netherlands-based company. Under this partnership, MGI will provide support to Predica in the development of targeted RNA sequencing tests utilizing MGI’s next-generation sequencing platforms. While the financial details of…
-
BGI Genomics’ Subsidiary Inks 3-Year Noninvasive Prenatal Test Agreement with Heilongjiang Province
•
BGI Genomics Co., Ltd (SHE: 300676), a leading genomics company based in China, has announced that its subsidiary, Heilongjiang BGI Longjiang Medical Laboratory Co., Ltd, has entered into a three-year cooperation agreement with the Health Commission of Heilongjiang Province. This agreement focuses on providing noninvasive prenatal genetic testing services for…
-
Kindstar Global and MGI Tech Co., Ltd. Form Partnership to Establish Multi-Omics Service Center in China
•
Kindstar Global (HKG: 9960), a biopharmaceutical company based in China, has announced a strategic partnership with fellow Chinese firm MGI Tech Co., Ltd. (SHA: 688114). This collaboration will result in the creation of Kindstar’s multi-omics DCS Lab service center, which will be focused on serving the Central China region. Kindstar…
-
Novartis Becomes First MNC to Publicly Adjust China CRDMO Partnerships in Response to BioSecure Act
•
Swiss pharmaceutical giant Novartis (NYSE: NVS) has reportedly become the first multinational corporation to publicly acknowledge actively revising its partnerships with China-based Contract Research, Development, and Manufacturing Organizations (CRDMOs) in light of the proposed BioSecure Act in the United States. During a press call with US media accompanying the company’s…
-
US Lawmakers Expand Scrutiny on Chinese Biotech Firms with Potential Military Ties
•
Despite his announced retirement from Congress effective April 19 this year, Mike Gallagher continues to influence discourse surrounding China’s biotech sector. This week, Gallagher, along with Republican Raja Krishnamoorthi, sent a letter to US Defense Secretary Lloyd Austin, inquiring about updates on a Pentagon security review of several Chinese biotechnology…
-
China’s CNIPA Upholds Patent for Nobel-Winning CRISPR/Cas9 Gene Editing Technology
•
The China National Intellectual Property Administration (CNIPA) has upheld a key patent surrounding the CRISPR/Cas9 gene editing technology, rejecting an invalidation challenge. The decision was announced by ERS Genomics Ltd, an Ireland-based company founded by Dr. Emmanuelle Charpentier, the Nobel prize-winning co-inventor of the technology, to manage and license access…
-
Bayer and Thermo Fisher Partner to Develop Rapid Companion Diagnostics for Precision Oncology
•
Germany’s Bayer (NYSE: BAYE) has entered into a strategic partnership with U.S. life sciences leader Thermo Fisher Scientific (NYSE: TMO) to develop next-generation sequencing (NGS)-based companion diagnostic assays (CDx) aimed at enhancing precision cancer therapies. Financial terms of the collaboration remain undisclosed. According to the press release, the diagnostic tests…
-
MGI Tech Lands Eurofins Genomics Deal for T20 Ultra-High Throughput Sequencer in Europe
•
MGI Tech (SHA: 688114), a China-based sequencing company, has announced a significant collaboration with Eurofins Genomics Europe Genotyping A/S, headquartered in France. As part of the deal, Eurofins has placed a corporate order for MGI’s DNBSEQ-T20×2 (T20) ultra-high throughput sequencer, which is accompanied by the genomics data center ZTRON Appliance,…
-
US Senate Puts Brakes on Bill Targeting China-Based CDMOs Amid Stock Market Reactions
•
A US Congress bill aimed at prohibiting US-funded entities from engaging with various China-based contract development and manufacturing organizations (CDMOs) has reportedly been sidelined by the Senate this week. The bipartisan legislation, which previously triggered a significant decline in stock prices for companies like WuXi AppTec (HKG: 2359, SHA: 603259),…
-
China-Based Biotechs Respond to US House Bill Limiting Federal Funding for ‘Concerning’ Companies
•
A bipartisan bill introduced on January 26, 2024, by members of the US House Select Committee on strategic competition between the US and China has caused a significant decline in the share prices of various China-based biotech and contract development organizations (CDOs) last week. The companies have begun to respond…
-
GSK In-Licenses Elegen’s Cell-Free DNA Tech to Advance Next-Gen Gene Therapies and Vaccines
•
GlaxoSmithKline (GSK; NYSE: GSK), a UK-based pharmaceutical giant, has this week in-licensed US partner Elegen’s cell-free DNA manufacturing technology to bolster the potential development of next-generation mRNA, cell, and viral gene therapies, as well as RNA-based vaccines. Elegen will receive upfront fees, purchase commitments, potential equity investment, and milestone payments…
-
Glorious Med and Illumina Join Forces for Advanced Urinary Tract Infection Detection
•
Hangzhou-based Glorious Med, a premier company specializing in gene detection for urinary system tumors, has entered into a partnership with US genomics giant Illumina (NSDQ: ILMN). The collaboration aims to advance the precise diagnosis of urinary tract pathogens and drug resistance genes through the use of Illumina’s Urinary Pathogen/Drug Resistance…
-
Mingyi Zhizao Secures $14 Million to Scale Gene Sequencing Platform and Production
•
Shenzhen Mingyi Zhizao Technology Co., Ltd, a Chinese company specializing in the gene sequencing industry, has reportedly secured nearly RMB 100 million (USD 14 million) in a Series B++ funding round led by Tenykin Capital and Jiangsu Jinqiao Private Equity Fund. The fresh capital is earmarked for the expansion of…
-
Haplox and Illumina Mark Milestone with Production of NextSeq 2000Dx-CN-HAP Sequencing System in China
•
Haplox Biotechnology Co., Ltd, a Chinese biotech firm, and US industry leader Illumina (NASDAQ: ILMN) have jointly announced the production line completion of the first NextSeq 2000Dx-CN-HAP gene sequencing system, a domestically produced product manufactured in Shenzhen. The collaboration will now concentrate on local manufacturing of high-end life sciences equipment…
-
Bio-Techne Corporation Reports 2% YOY Revenue Growth in Q1 2024 Fiscal Report
•
US-based life sciences service provider Bio-Techne Corporation (NASDAQ: TECH) has released its Q1 report for the fiscal year 2024, which ended on September 30, 2023. The company reported a 2% year-on-year (YOY) increase in revenues, reaching USD 276.9 million. Segment Performance and Revenue BreakdownBio-Techne’s Protein Sciences segment contributed USD 204.7…
-
Canada’s SGC Partners with HitGen to Enhance Drug Discovery Using DEL Technology
•
The Structural Genomics Consortium (SGC) of Canada has announced a strategic partnership with China-based HitGen Inc. (SHA: 688222). This collaboration will leverage HitGen’s DNA-encoded library (DEL) technology platform to screen under-represented targets identified by SGC. The resulting screening datasets will be made available on a publicly accessible portal, enabling global…
-
Vela Diagnostics Partners with SRL Inc. to Expand Molecular Diagnostics in Japan
•
Singapore-based Vela Diagnostics, a global leader in integrated molecular solutions for diagnosing infectious diseases and cancer, has announced a strategic research collaboration with SRL Inc., a premier Japanese healthcare service provider. This partnership is designed to enhance the distribution of Vela Diagnostics’ advanced molecular diagnostic solutions within Japan, although financial…
